Literature DB >> 12686811

Patterns of care for the treatment of bladder cancer.

Claire Snyder1, Linda Harlan, Kevin Knopf, Arnold Potosky, Richard Kaplan.   

Abstract

PURPOSE: We examined bladder cancer patterns of care and differences in treatments administered to patients by age, race/ethnicity and gender using a population based sample.
MATERIAL AND METHODS: A random sample of bladder cancer patients diagnosed in 1995 without upper urinary tract involvement in 8 Surveillance, Epidemiology and End Results registries were included. Tumor stage and grade were used to assign patients to risk groups and patterns of care were investigated. Descriptive analyses and logistic regression models examined differences in care based on patient age, race/ethnicity and gender.
RESULTS: Of the 669 patients 485 patients had superficial disease, including 222 at low, 151 at intermediate and 112 at high risk, while 154 had muscle invasive disease. Of the patients with superficial bladder cancer 73.4% underwent transurethral bladder resection only. Those with muscle invasive disease were most commonly treated with transurethral bladder resection only (49.1%) or cystectomy only (31%). Intravesical chemotherapy in patients with superficial tumors and aggressive treatment with cystectomy and/or systemic chemotherapy in those with muscle invasive disease increased in relation to risk classification, as may have been expected. However, multivariate analyses suggested an influence of co-morbidities on intravesical therapy in patients with superficial tumors and an influence of patient age and geographic region on aggressive treatment for muscle invasive disease.
CONCLUSIONS: No differences in treatment were identified based on patient race/ethnicity or gender. Treatment for superficial disease is primarily influenced by risk category and co-morbidities, while treatment for muscle invasive disease is influenced by patient age and geographic region.

Entities:  

Mesh:

Year:  2003        PMID: 12686811     DOI: 10.1097/01.ju.0000056727.30546.b7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

Review 1.  Neoadjuvant chemotherapy for bladder cancer.

Authors:  Peter C Black; Gordon A Brown; H Barton Grossman; Colin P Dinney
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.

Authors:  Gary H Lyman; Nicole M Kuderer; Stephen J Freedland
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

3.  Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.

Authors:  Zhongbo Liu; Xia Xu; Xuesen Li; Shuman Liu; Anne R Simoneau; Feng He; Xue-Ru Wu; Xiaolin Zi
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-11

4.  Optimizing care and outcomes of patients with muscle-invasive bladder cancer.

Authors:  Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

5.  Treatment and outcome in muscle invasive bladder cancer: a population-based survey.

Authors:  Anna M Leliveld; Benjamin H J Doornweerd; Esther Bastiaannet; Michael Schaapveld; Igle J de Jong
Journal:  World J Urol       Date:  2010-04-10       Impact factor: 4.226

6.  Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice.

Authors:  Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

7.  The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.

Authors:  Florian R Schroeck; Kristine E Lynch; Zhongze Li; Todd A MacKenzie; David S Han; John D Seigne; Douglas J Robertson; Brenda Sirovich; Philip P Goodney
Journal:  Cancer       Date:  2019-05-23       Impact factor: 6.860

8.  [Influence of older age on survival after radical cystectomy due to urothelial carcinoma of the bladder: survival analysis of a German multi-centre study after curative treatment of urothelial carcinoma of the bladder].

Authors:  M May; H-M Fritsche; C Gilfrich; S Brookman-May; M Burger; W Otto; C Bolenz; L Trojan; E Herrmann; M S Michel; C Wülfing; A Tiemann; S C Müller; J Ellinger; A Buchner; C G Stief; D Tilki; W F Wieland; T Höfner; M Hohenfellner; A Haferkamp; J Roigas; O Müller; P Bretschneider-Ehrenberg; M Zacharias; S Gunia; P J Bastian
Journal:  Urologe A       Date:  2011-07       Impact factor: 0.639

9.  WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.

Authors:  Yaxiong Tang; Anne R Simoneau; Wu-xiang Liao; Guo Yi; Christopher Hope; Feng Liu; Shunqiang Li; Jun Xie; Randall F Holcombe; Frances A Jurnak; Dan Mercola; Bang H Hoang; Xiaolin Zi
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

10.  Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

Authors:  Brent K Hollenbeck; Zaojun Ye; Rodney L Dunn; James E Montie; John D Birkmeyer
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.